Guselkumab in psoriatic arthritis: a profile of its use
Declarations
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Y. N. Lamb is a salaried employee of Adis International Ltd./Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Q&A can be found here
Abstract
Guselkumab (TREMFYA®), a fully human immunoglobulin G1λ (IgG1λ) monoclonal antibody that selectively targets
interleukin (IL)-23, is an effective and generally well-tolerated treatment option for active psoriatic arthritis. Guselkumab
is administered subcutaneously and can be used alone or in combination with methotrexate. In randomized, double-blind,
placebo-controlled phase 3 trials in adults with active psoriatic arthritis and an inadequate response to or intolerance of
standard treatment, guselkumab was effective in reducing disease activity and structural damage progression. Guselkumab
conferred improvements in arthritis, enthesitis, dactylitis, psoriasis, axial symptoms, physical function and health-related
quality of life. The clinical benefits of guselkumab for the diverse signs and symptoms of psoriatic arthritis increased or
were maintained through two years of treatment, with no new safety signals emerging.
© Springer Nature Switzerland AG 2021
